The Trump administration has opened a formal trade investigation into Germany's pharmaceutical pricing system, escalating a long-running dispute over global drug costs and raising the prospect of new tariffs on one of Europe's largest healthcare exporters.
The investigation, announced by U.S. Trade Representative Jamieson Greer on June 18, marks the first time President Donald Trump's campaign to reshape international drug pricing has been converted into a country-specific trade enforcement action. Washington argues that Germany's pricing policies force American consumers to shoulder an unfair share of the costs associated with pharmaceutical innovation and research.
The case was launched under Section 301 of the Trade Act of 1974, the same legal authority frequently used by the Trump administration to challenge foreign trade practices. U.S. officials will now examine whether Germany's policies are "unreasonable or discriminatory and burdens or restrict U.S. commerce," according to the investigation notice.
At the center of the dispute are mechanisms used by Germany's healthcare system to lower medicine costs, including confidential pricing agreements and mandatory manufacturer rebates. U.S. officials contend those measures suppress revenues for innovative drugmakers and shift research-and-development costs onto American patients.
"President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," Greer said. He also criticized Berlin's efforts to pursue additional pharmaceutical savings, calling them "a serious step backwards."
The investigation stems from Trump's May 2025 executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients." The order directed federal agencies to challenge foreign governments whose healthcare systems obtain lower drug prices than those paid in the United States.
Administration officials argue that while the U.S. accounts for less than 5% of the global population, it generates a disproportionate share of pharmaceutical industry profits that help finance future treatments and medical breakthroughs.
Health and Human Services Secretary Robert F. Kennedy Jr. endorsed the move, saying, "fighting the war against disease is a shared burden across wealthy nations." Kennedy argued that higher reimbursement rates abroad would create a more balanced system for funding innovation.
The administration has pointed to a recent agreement with the United Kingdom as evidence that negotiations can succeed. According to Greer, Britain agreed to pay higher prices for certain innovative medicines earlier this year in exchange for avoiding tariff measures.
Germany, however, faces significant domestic financial pressures. The country's statutory health insurance system is grappling with an estimated €20 billion funding gap, prompting policymakers to seek cost reductions rather than higher spending on medicines.
German Health Minister Nina Warken indicated that Berlin has little room to increase pharmaceutical expenditures.
"We have a tense financial situation in our health insurance system," Warken said.
The dispute has placed Germany's pharmaceutical industry in a difficult position. The country serves as a major manufacturing hub for companies including Bayer, Boehringer Ingelheim and Merck KGaA, all of which could face uncertainty if trade tensions escalate.
Industry groups on both sides of the Atlantic have responded cautiously. Germany's VCI industry federation warned that companies require stability and long-term planning certainty, while the U.S. Chamber of Commerce supported the investigation but emphasized that negotiations should remain the preferred outcome.
Key dates in the investigation include:
- August 10, 2026: Deadline for public comments.
- September 22, 2026: USTR public hearing.
- Ongoing consultations between Washington and Berlin.
